bluebird bio, Inc. 4

4 · bluebird bio, Inc. · Filed Feb 16, 2017

Form 4

Period: 2017-02-14

Director

Transactions

Exercise/Conversion
Common Stock
2017-02-14$25.16/sh+1,950$49,062→ 6,950 total
Exercise/Conversion
Stock Option (right to buy)
2017-02-14+1,950→ 5,550 total
Exercise: $25.16Exp: 2024-06-11→ Common Stock (1,950 underlying)
Exercise/Conversion
Stock Option (right to buy)
2017-02-14+4,000→ 0 total
Exercise: $21.43Exp: 2024-01-08→ Common Stock (4,000 underlying)
Exercise/Conversion
Common Stock
2017-02-14$21.43/sh+4,000$85,720→ 5,000 total
Sale
Common Stock
2017-02-14$80.01/sh−5,950$476,076→ 1,000 total

Footnotes (4)

[F1]This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 13, 2016.
[F2]The range in prices for the transaction reported on this line was $80.00 to $80.15. The average weighted price was $80.0128. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F3]This option vests ratably over three years in annual installments, commencing on January 8, 2014.
[F4]This option vests 100% on the earlier of June 11, 2015 or the date of the next annual meeting of stockholders.

Documents

1 file